"After looking at the data on this drug, collaborating with the CDC
 and FDA and speaking with the patient and his family, we decided this 
was currently our best option for treatment," said Dr. Phil Smith, the 
medical director of the biocontainment unit at Nebraska Medical Center 
where Ashoka Mukpo is being treated.
What to Know About the Experimental Drug Being Given to the Texas Ebola PatientTexas Ebola Patient Thomas Eric Duncan Now Getting Experimental Drug
Both Mukpo, a freelance cameraman who was working with NBC in Liberia
 when he tested positive for the disease, and Thomas Eric Duncan, a 
Liberian man visiting family in America, are being treated with brincidofovir.
"Every
 patient is somewhat different, and we believe Brincidofovir is the best
 choice," Smith said in a statement released today.
The
 drug is produced by a North Carolina-based biopharmaceutical company 
and was authorized by the Food and Drug Administration for use in 
specific, experimental cases.
Mukpo
 left Monrovia, Liberia on Sunday night and arrived in Omaha on Monday 
morning. His parents saw him as he was taken off the plane and said at a
 press conference Monday that they were happy his conditions had not 
worsened dramatically since leaving Africa.
Duncan remains in critical condition and he is described as stable. He is on a ventilator and receiving kidney dialysis,
 according to a release today from the Texas Health Presbyterian 
Hospital in Dallas. Duncan's liver function, which declined over the 
weekend, has improved, the hospital said.
No comments :
Post a Comment